Items tagged with Research and development

Stop TB Partnership and Bamboo Capital Partners to re-imagine TB care by deploying blended finance investments in TB affected countries (post)

16 June 2021, Geneva, Switzerland - The Stop TB Partnership and Bamboo Capital Partners, an impact investing platform, signed a partnership agreement to support small- and medium-enterprises and start-ups, particularly from TB affected countries, developing impactful health technologies for TB, COVID-19, and TB co-morbidities.

Launch of UNITE4TB partnership marks a new era in TB treatment development (post)

The partnership will accelerate the development of new TB drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortium.

LSHTM launches new centre of innovation to tackle antimicrobial resistance and TB (post)

The London School of Hygiene & Tropical Medicine’s (LSHTM) research into tackling antimicrobial resistance and tuberculosis has been boosted through a new partnership with Johnson & Johnson.

Spanish pharmaceutical company Zendal and IAVI partner to advance the TB vaccine candidate MTBVAC into efficacy trials (post)

-- TB kills 1.4 million people a year, an infectious disease toll only recently surpassed by COVID-19.
-- COVID-19 has reversed years of progress in TB response, costing additional lives and adding to the urgency of the global TB problem.
-- MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.

WHO position statement on innovative clinical trial designs for development of new TB treatments (post)

The World Health Organization (WHO) is publishing a position statement on Innovative Clinical Trial Designs for Development of New TB Treatments. This document aims to support TB regimen development by highlighting key clinical trial characteristics to help advance novel therapies. It summarises key innovations in TB clinical trial designs, ranging from pharmacokinetic-pharmacodynamic (PK-PD) modelling and new advances in biomarker development to the value of novel clinical trial design methodologies and post-licensure observational studies.

Episode 4 of WGND podcast now available online (post)

Episode 4 of the podcast series, The Dose, by the Stop TB Partnership's Working Group on New TB Drugs (WGND) is now available online. Shobha Shukla speaks with TB regimen development experts Dr. Debra Hanna and Dr. Robert Bates on the topic of the PAN-TB collaboration and novel regimen development.

Global Forum on TB Vaccines 2021: Meeting report (post)

The Global Forum on TB Vaccines was held virtually on 20-22 April 2021, marking its 20th anniversary. The Global Forum on TB Vaccines is the world's largest gathering of stakeholders striving to develop new vaccines to prevent TB.

GHIT Fund announces new investments: A total of 750 million yen in drugs for malaria and Chagas disease, vaccine for malaria, and diagnostics for TB (post)

The Global Health Innovative Technology (GHIT) Fund announced a total of approximately 750 million yen (US$6.6 million) to invest in six partnerships to develop new lifesaving drugs for malaria and Chagas disease, a vaccine for malaria, and diagnostics for TB.

Pediatric TB research and development: Progress, priorities and funding opportunities (post)

Worrying lack of funding for TB (post)

A report from the Stop TB Partnership and Treatment Action Group in December highlighted the woefully inadequate funding allocated to tuberculosis research. Priya Venkatesan reports.